Grants & Programs

Schedule and Dose for Combination Therapy

Date:
March 17, 2011
Time:
07:00 AM
Location:
Gaylord National Hotel and Convention Center, National Harbor, MD

The Cancer Immunotherapy Consortium held its annual Scientific Colloquium on March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD. The meeting, “Schedule and Dose for Combination Therapy,” featured a series of plenary lectures examining how best to address the challenges of combining immune-based treatments with existing standards of care. The meeting also included an interdisciplinary roundtable discussion addressing the academia-industry interface and how it can help shape the future of Immuno-Oncology.


Introduction

  • Axel Hoos, Bristol-Myers Squibb


Keynote Address

  • Rafi Ahmed, Emory University


Studying Vaccination Schedules: Lessons from Infectious Diseases

  • Martin G. Myers, University of Texas Medical Branch
  • Yves Levy, University Paris-Est, Publique-Hôpitaux de Paris (AP-HP), Groupe Henri-Mondor Albert-Chenevier
  • Rafick-Pierre Sékaly, Vaccine & Gene Therapy Institute,
  • Gisela González Marinello, Center of Molecular Immunology


Schedule and Dose: Relevance for Combination Therapy

Introduction by Laurence Zitvogel, Institut Gustave Roussy

Immune Therapy & Immune Therapy

  • James L. Gulley, National Cancer Institute, NIH
  • Cornelis J.M. Melief, Leiden University Medical Center
  • Svetomir N. Markovic, Mayo Clinic
  • Robert H. Vonderheide, Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine


Immune Therapy & Chemotherapy

  • Tania Crombet Ramos, Center of Molecular Immunology
  • Jean-Marie Cuillerot, Bristol-Myers Squibb
  • Leisha A. Emens, Johns Hopkins University School of Medicine
  • Hyam Levitsky, Johns Hopkins University School of Medicine
  • Frédéric Triebel, Immutep S.A.


Immune Therapy & Targeted Therapies

  • Charlotte E. Ariyan, Memorial Sloan-Kettering Cancer Center,
  • Margaret Callahan, Memorial Sloan-Kettering Cancer Center
  • Javier Pinilla-Ibarz, H. Lee Moffitt Cancer Center and Research Institute
  • Antoni Ribas, University of California Los Angeles
  • Lupe G. Salazar, University of Washington School of Medicine
  • Laurence Zitvogel, Institut Gustave Roussy


Immune Therapy & Local Therapies

  • Silvia C. Formenti, New York University School of Medicine
  • Jeffrey A. Gelfand, Massachusetts General Hospital
  • Ronald Levy, Stanford University School of Medicine


The Academia-Industry Interface: Crosstalk to Shape the Future of Immuno-Oncology

  • Axel Hoos, Bristol-Myers Squibb
  • Adam Kolom, Cancer Research Institute
  • Christoph Huber, University Medical Center of the Johannes Gutenberg-University of Mainz
  • Michael D. Becker, MD Becker Partners LLC


Interdisciplinary Roundtable

Moderated by Jill O’Donnell-Tormey, Cancer Research Institute & Axel Hoos, Bristol-Myers Squibb

  • Michael D. Becker, MD Becker Partners LLC
  • Stephen P. Creekmore, National Cancer Institute, NIH
  • Tito Fojo, National Cancer Institute
  • Mark W. Frohlich, Dendreon Corporation
  • F. Stephen Hodi Jr., Dana-Farber Cancer Institute
  • Christoph Huber, University Medical Center of the Johannes Gutenberg-University of Mainz
  • Nils Lonberg, Bristol-Myers Squibb
  • Michele Maio, University Hospital of Siena
  • Jens-Peter Marschner, Merck Serono
  • Raj K. Puri, U.S. Food & Drug Administration
  • Shalini Sharp, Agenus Inc.
  • Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center


Immunobiology & Immune Monitoring

Keynote Address by Mark M. Davis, Stanford University School of Medicine

Treg Homeostasis

  • Mark M. Davis, Stanford University School of Medicine
  • Jens G. Lohr, Dana-Farber Cancer Institute and Broad Institute
  • Benoit L. Salomon, Université de Pierre et Marie Curie, Centre National de Recherche Scientifique and INSERM
  • Sjoerd H. van der Burg, Leiden University Medical Center


Immune Monitoring Session

  • Michael Kalos, University of Pennsylvania School of Medicine
  • Cedrik M. Britten, University Medical Center of the Johannes Gutenberg-University Mainz
  • Sylvia Janetzki, ZellNet Consulting, Inc.
  • Lisa K. McNeil, Pfizer Vaccine Research
  • Axel Hoos, Bristol-Myers Squibb


Contact Us

Want to learn more about the Cancer Immunotherapy Consortium? Contact a CIC representative at consortium@cancerresearch.org or (212) 688-7515.